# Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

> **NCT01516970** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag G.m.b.H** · enrollment: 312 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)

## Interventions

- **DRUG:** Darunavir/Ritonavir (DRV/r)
- **DRUG:** Lopinavir in fixed combination with Ritonavir
- **DRUG:** Zidovudine
- **DRUG:** NRTIs
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT01516970
- **Lead sponsor:** Janssen-Cilag G.m.b.H
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-25
- **Primary completion:** 2013-08-01
- **Final completion:** 2013-09-28
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2017-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516970, "Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01516970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*